Case of newly diagnosed primary immunodeficiency at age 65

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Low awareness of doctors of various specialties about such an initial defect in immunity as hereditary angioedema leads to poor detection of this disease, as a result of which patients often receive ineffective drugs for a long time and are at risk of developing life-threatening complications.

A clinical case was presented of a patient whose diagnosis of hereditary angioedema was first established at the age of 65 despite a long history of edema. There were no urticarial rashes. For edema for 3 years, the patient took Loratadine, systemic glucocorticosteroids were repeatedly administered. In addition, for many years she was worried about abdominal syndrome with an episode rate of up to several times a week, for the purpose of stopping which she used Tempalgin. There is a burdened family history of angioedema. This hospitalization was due to the development of edema of the lower lip and left cheek, the appearance of which is associated with a bite of the inner side of the cheek in sleep, there was no effect from the use of systemic glucocorticosteroids and antihistamines. The examination revealed a decrease in both the amount and functional activity of the C1-inhibitor, thus, hereditary angioedema of type I was diagnosed. Genetic examination revealed a previously undescribed variant of mutations in the SERPING1 gene.

The pathogenesis of edema in hereditary angioedema is due to the accumulation of bradykinin, therefore, the use of glucocorticosteroids and antihistamines is ineffective. Currently, there are modern highly effective and safe means, both for stopping and for the prevention of such edema.

It is important to inform specialists of various profiles about this disease and the principles of its therapy.

Full Text

Restricted Access

About the authors

Irina V. Demko

Professor V.F. Voino-Yasenetsky Krasnoyarsk State Medical University; Krasnoyarsk Clinical Regional Hospital

Email: demko64@mail.ru
ORCID iD: 0000-0001-8982-5292
SPIN-code: 6520-3233

MD, Dr. Sci. (Med.), Professor

Russian Federation, Krasnoyarsk; Krasnoyarsk

Elena A. Sobko

Professor V.F. Voino-Yasenetsky Krasnoyarsk State Medical University; Krasnoyarsk Clinical Regional Hospital

Email: sobko29@mail.ru
ORCID iD: 0000-0002-9377-5213
SPIN-code: 9132-6756

MD, Dr. Sci. (Med.), Professor

Russian Federation, Krasnoyarsk; Krasnoyarsk

Natalia A. Shestakova

Professor V.F. Voino-Yasenetsky Krasnoyarsk State Medical University; Krasnoyarsk Clinical Regional Hospital

Email: barsk@rambler.ru
ORCID iD: 0000-0002-2252-7423
SPIN-code: 4579-4502

MD, Cand. Sci. (Med.)

Russian Federation, Krasnoyarsk; Krasnoyarsk

Angelina Y. Kraposhina

Professor V.F. Voino-Yasenetsky Krasnoyarsk State Medical University; Krasnoyarsk Clinical Regional Hospital

Author for correspondence.
Email: angelina-maria@inbox.ru
ORCID iD: 0000-0001-6896-877X
SPIN-code: 8829-9240

MD, Cand. Sci. (Med.), Associate Professor

Russian Federation, Krasnoyarsk; Krasnoyarsk

References

  1. Draft clinical recommendations. Hereditary angioedema. Moscow; 2022. 62 р. (In Russ).
  2. Russian Association of Allergists and Clinical Immunologists. Federal clinical guidelines for the diagnosis and treatment of patients with angioedema. Moscow; 2013. 29 р. (In Russ).
  3. Bork K, Aygören-Pürsün E, Bas M, et al. Guideline: Hereditary angioedema due to C1 inhibitor deficiency. Allergo J. Int. 2019; 28(1):16–29. doi: 10.1007/s40629-018-0088-5
  4. Santacroce R, D’Andrea G, Maffione AB, et al. The genetics of hereditary angioedema: A review. J Clin Med. 2021;10(9):2023. doi: 10.3390/jcm10092023
  5. Maurer M, Magerl M, Betschel S, et al. The international WAO/EAACI guideline for the management of hereditary angioedema: The 2021 revision and update. Allergy. 2022;77(7):1961–1990. doi: 10.1111/all.15214
  6. Zotter Z, Csuka D, Szabó E, et al. The influence of trigger factors on hereditary angioedema due to C1-inhibitor deficiency. Orphanet J Rare Dis. 2014;9(44):1–6. doi: 10.1186/1750-1172-9-44
  7. Marcelino-Rodriguez I, Callero A, Mendoza-Alvarez A. Bradykinin-Mediated angioedema: An update of the genetic causes and the impact of genomics. Front Genet. 2019;(10):900 doi: 10.3389/fgene.2019.00900
  8. Cicardi M, Banerji A, Bracho F, et al. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med. 2010; 363(6):532–541. doi: 10.1056/NEJMoa0906393
  9. Craig TJ, Rojavin MA, Machnig T, et al Effect of time to treatment on response to C1 esterase inhibitor concentrate for hereditary angioedema attacks. Ann Allergy Asthma Immunol. 2013;111(3): 211–215. doi: 10.1016/j.anai.2013.06.021
  10. Banerji A, Riedl MA, Bernstein JA, et al. Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks. JAMA. 2018;320(20):2108–2121. doi: 10.1001/jama.2018.16773

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright © Pharmarus Print Media, 2023



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies